ArticleTurkish journal of chemistry2025
Levothyroxine combined with selenium nanoparticles in one liposomal delivery system for hypothyroidism.
Article in Turkish journal of chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent Advances in the Treatment of Thyroid Pathologies with Selenium-Containing Compounds, Nanoparticles and Nanocomplexes Based on Selenium and Selenoproteins.Biological trace element research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Levothyroxine, as a thyroid-stimulating hormone, is the primary drug used for hypothyroidism treatment, but it has poor bioavailability. Selenium (Se) plays an important role in regulating thyroid function; moreover, selenium nanoparticles (SeNPs) offer advantages over other Se forms. Liposomal delivery systems, especially those coated with polyethylene glycol (PEG), can increase the oral bioavailability of drugs and provide controlled release. In our research, as described in this paper, we aimed to develop an orally applicable liposomal delivery system to achieve enhanced treatment of hypothyroidism with SeNP characteristics, controlled levothyroxine release, and improved bioavailability of both drug and SeNPs. The SeNPs have been prepared using ascorbic acid with a hydrothermal method and an ecofriendly approach. The SeNPs have been 75-100 nm in size and have shown a Fourier transform infrared spectroscopy (FTIR) peak at 479 cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.